SCHEMBL7543870

SCHEMBL7543870

CCCCOc1ccc(S(=O)(=O)N(C[C@H](O)COc2cccc3[nH]c4ccccc4c23)C2CCNCC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 15/20 0.60
ADRB1 P08588 6/20 0.49
ADRB2 P07550 8/20 0.45
DNM1 Q05193 2/20 0.44
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
KCNH2 Q12809 2/20 0.43
DRD2 P14416 3/20 0.42
KDM4E B2RXH2 1/20 0.42
TLR4 O00206 1/20 0.42
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
MLNR O43193 1/20 0.42
NR1I2 O75469 1/20 0.42
KCNK2 O95069 1/20 0.42
ABCB11 O95342 1/20 0.42
APP P05067 1/20 0.42
ABCB1 P08183 1/20 0.42
HTR1A P08908 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7226984 0.92 ADRB3 (0.60) ADRB3ADRB1ADRB2DNM1SLC6A2
SCHEMBL6986206 0.77 ADRB3 (0.67) ADRB3ADRB1ADRB2DNM1TLR4
SCHEMBL6985948 0.76 ADRB3 (0.69) ADRB3ADRB1ADRB2TLR4
SCHEMBL7138803 0.75 ADRB3 (0.83) ADRB3ADRB1ADRB2SLC6A2SLC6A4
SCHEMBL6980970 0.75 ADRB3 (1.00) ADRB3ADRB1ADRB2DNM1
SCHEMBL6986334 0.75 ADRB3 (0.86) ADRB3ADRB1ADRB2DNM1SLC6A2
SCHEMBL6982327 0.74 ADRB3 (0.91) ADRB3ADRB1ADRB2DNM1
SCHEMBL6074935 0.72 ADRB3 (0.55) ADRB3ADRB1ADRB2DNM1TLR4
SCHEMBL7133464 0.72 ADRB3 (0.65) ADRB3ADRB1ADRB2DNM1SLC6A2
SCHEMBL7542782 0.71 ADRB3 (0.61) ADRB3ADRB1ADRB2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6498170-B2 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS WYETH 2002-12-24 US disclosed
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 ADRB3 1/4885ADRB1 2/4885ADRB2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.